Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age
An Open-Label Study To Evaluate The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age In Usual Care Settings
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Terminated
See termination reason in detailed description.
Other terminated trials from Wyeth is now a wholly owned subsidiary of Pfizer
- Postmenopause · Aug 2010
- Ankylosing Spondylitis · Jul 2010
- Rheumatoid Arthritis · Phase PHASE4 · May 2010
- Fractures · Phase PHASE2/PHASE3 · Mar 2010
- Healthy Subjects · Phase PHASE1 · Apr 2009
See all terminations from Wyeth is now a wholly owned subsidiary of Pfizer
A PHASE3 clinical study on Hemophilia A, this trial is terminated or withdrawn. The trial is conducted by Wyeth is now a wholly owned subsidiary of Pfizer and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2022 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.